Lupus & antiphospholipid syndrome
Peripheral blood CD19+B cell proportion at baseline predicts early complete response to belimumab treatment in patients with refractory lupus nephritis
Authors' conclusion
Findings support the baseline CD19+B cell proportion could be used to predict CR to treatment with belimumab in refractory lupus nephritis patients.
Study context
- Population
- Patients with refractory LN who received 6 months of belimumab
- Participants
- 28 patients
- Exposure
- Baseline CD19+ B cell proportion in complete response (CR) vs non-CR patients
- Outcome
- Predictors of CR to belimumab
- Follow-up
- 6 months
Methodological detailsbinary logistic regression, ROC analysis
- Binary logistic regression
- ROC analysis
Main finding
As reported in the abstract
Baseline CD19+ B cell proportion as predictor of CR
Estimate (95% CI)P value
Baseline CD19+ B cell proportion
OR (univariate) 1.359(1.098–1.683)
P = 0.005Baseline CD19+ B cell proportion
OR (exploratory multivariate, adjusted for 24-hour urinary protein) 1.349(1.092–1.665)
P = 0.005- ROC cut-off of CD19+ B cell proportion
- 15.12%
- Sensitivity
- 90.90%
- Specificity
- 88.20%
- AUC
- 0.888 (95% CI 0.759 to 1.000, p=0.001)
Observational data: associations, not effects.
Further findings
Renal response at 6 months
- CR
- 39.29%
- Partial response (PR)
- 32.14%
- No response (NR)
- 28.57%
Original publication
Peripheral blood CD19+B cell proportion at baseline predicts early complete response to belimumab treatment in patients with refractory lupus nephritis. Lupus Sci Med. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →